Impact Factor 3.648 | CiteScore 3.99
More on impact ›

Methods ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Neurosci. | doi: 10.3389/fnins.2019.00877

An effective method for acute vagus nerve interfacing in experimental inflammation

  • 1Karolinska Institute (KI), Sweden
  • 2Feinstein Institute for Medical Research, United States
  • 3Northwell Health, United States
  • 4SetPoint Medical, Inc., United States

Neural reflexes regulate inflammation and electrical activation of the vagus nerve reduces inflammation in several models of inflammatory disease. These discoveries have generated an increasing interest in targeted neurostimulation as specific treatment for chronic inflammatory diseases. Data from the first clinical trials that use vagus nerve stimulation in treatment of rheumatoid arthritis and Chron´s disease suggest that there is a therapeutic potential of electrical vagus nerve stimulation in diseases characterized by excessive inflammation. Accordingly, there is an interest to further explore the molecular mechanisms and therapeutic potential of electrical vagus nerve stimulation experimentally in a range of experimental settings and available genetic mouse models of disease. Here, we describe a simple method for consistent electrical vagus nerve stimulation in the mouse.

Keywords: Bioelectronic medicine, Vagus nerve stimulation or VNS, neural reflex, Inflammation, Inflammatory reflex, peripheral nerve, Neural control

Received: 15 May 2019; Accepted: 05 Aug 2019.

Copyright: © 2019 Caravaca, Gallina, Tarnawski, Tracey, Pavlov, Levine and Olofsson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mx. April S. Caravaca, Karolinska Institute (KI), Solna, Sweden, april.caravaca@ki.se